While previous studies have shown that PRMT5 is overexpressed in CRC cells in general, our results revealed that PRMT5 expression is upregulated, as well as positively correlated with KRAS expression, in CRC patient datasets. This evidence concerns the gene KRAS and colorectal carcinoma.